PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$46.05
0.59 (1.30%)
▲
5d:
-1.33%
30d:
-4.52%
90d:
-26.65%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -7.9% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -7.9% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.28
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$46.12
0.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $46.05, which is considered oversold relative to its 30-day fair value range of $46.07 to $48.16. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.6) compared to its historical average (12.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.9% over the next few years. This pessimistic expectation contrasts with the company's recent 12.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PBH is in a strong downtrend. The price is currently testing key support at $45.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $66.80 (+45.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBH is in a strong downtrend. The price is currently testing key support at $45.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $66.80 (+45.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$46.07 -
$48.16
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.1% below Wall St target ($66.80)
Trading Range Analysis
30-Day Trading Range
$46.07 -
$48.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$45.22
Resistance Level
$49.81
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.62
Wall Street Target
$66.80
(+45.1%)
Revenue Growth (YoY)
-5.0%
Earnings Growth (YoY)
12.4%
Profit Margin
17.5%
Valuation Discount vs History
-7.9% cheaper
PE vs Historical
9.6 vs 12.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.9%
(market-implied from PE analysis)
1-Year Target
$42.41
(-8%)
2-Year Target
$39.06
(-15%)
3-Year Target
$35.98
(-22%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$46.02
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 5.5%)
$122.40
(+166%)
Base:
(SPY PE: 9.6, Growth: 5.5%)
$54.04
(+17%)
Bear:
(PE: 8.2, Growth: 5.5%)
$45.94
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 11.63 | Current EPS (TTM): $3.91
Bull Case
$61.25
(+33%)
Analyst growth 22.5%, PE expands to 12.8
Base Case
$55.68
(+21%)
Market implied 22.5%, PE stable at 11.6
Bear Case
$30.91
(-33%)
Severe decline -20.0%, PE contracts to 9.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.6 to 12.3
Stabilization Target:
$58.90
(+27.9%)
PE Expansion Potential:
+27.9%
Share & Embed Analysis
Last updated: June 23, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey Zerillo
SELL
1000 shares
2026-02-11
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
